Drug Resistant Tuberculosis in Oyo State, Nigeria: A Retrospective Study

Main Article Content

Stephen Oluwasegun Adetunji


Aim: The focus of this work was to evaluate the prevalence of rifampicin resistant tuberculosis in Oyo State, Nigeria.

Study Design:  A cross sectional retrospective study

Place and Duration of Study: St Mary’s Catholic Hospital, Ibadan, Nigeria, between October 2016 and March 2018

Methodology: In this study, 1044 patients diagnosed in the GeneXpert laboratory was conducted using the laboratory register. The age, gender, HIV Status, MTB analysis results and resistance to rifampicin were collected and analyzed.

Results: Of the 1044 tested, 177 (17%) tested positive for TB while 19 (10.7%) of the 177 were resistant to rifampicin. Fourteen (73.7%) of the 19 were male and 5 (26.3%) were female. Fourteen (73.7%) of the 19 fell between 21 - 40 years of age. Seven (36.8%) of the 19 resistant to rifampicin were HIV positive. Of the total 1044 patients tested, 601 (57.6%) were females and 443 (44.4%) were male.

Conclusion: This study showed that rifampicin resistant tuberculosis is high in Nigeria especially among the economically productive age group in the country. More attention should be committed to quick accessibility of diagnosis, treatment and monitoring by the policymakers.

Rifampicin, drug resistant, tuberculosis, Nigeria.

Article Details

How to Cite
Adetunji, S. O. (2020). Drug Resistant Tuberculosis in Oyo State, Nigeria: A Retrospective Study. International Journal of TROPICAL DISEASE & Health, 41(2), 39-45. https://doi.org/10.9734/ijtdh/2020/v41i230253
Original Research Article


World Health Organization Global Tuberculosis Report. 2017;4.

WHO Tuberculosis Fact sheet. 2016; 104.
Available:www.who.int.org/mediacentre/ factsheet/fs104/.

Espinal MA, Laszlo A, Simonsen L. Global trends in resistance to anti-tuberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surve-illance. N Eng J Med. 2001;344:1294- 303.

Mukherjee JS, Rich ML, Socci AR. Programmes and principles for manage-ment of multidrug resistant tuberculosis. The Lancet. 2004;372:474–481.

Chemhuru M, Duka M, Joseph K. Implementation of Xpert MTB/RIF assay in Buhera District, Zimbabwe: Lessons learned; 2016.
Available:www.msf.org.za/download/ file/fid/4653

Cepheid Gene X pert GXMTB/RIF-10. Operator Manual. 2010;300.

UNAIDS. HIV and AIDS estimates; 2014. Available:www.unaids.org/en/ regioncountries/countries/nigeria

WHO Nigeria support for Rapid Scaling-Up of Programmatic Management of Drug-Resistant Tuberculosis in Nigeria; 2016. Available:www.afro.int/en/n

Rasaki SO, AJibola AA, Musa SA. Rifampicin resistant tuberculosis in a secondary health institution in Nigeria, West Africa. J Infect Dis Ther. 2014;2:139. DOI: 10.4172/2332-0877.1000139

Adetunji SO, Donbraye E, Ekong MJ, Adetunji BI. Rifampicin resistant tuberculosis among known HIV infected people in Oyo State, Nigeria. Journal of Immuniassay and Immunochemistry. 2019; 40(3):289-299.

Audu ES, Gambo MS, Yakubu AA. Rifampicin resistant mycobacterium tuberculosis in Nasarawa State, Nigeria. Niger J Basic Clin Sci. 2017;14:21-5.

Nwadioha SI, Nwokedi EO, Ezema GC. Drug Resistant Mycobacterium tuberculosis in Benue, Nigeria. Br Microbiol Res J. 2014;4:988-95.

Daniel O, Osman E. Prevalence and risk factors associated with drug resistant Tuberculosis in South West Nigeria. Asian Pac J Trop Med. 2011;4:148-51.

Bello LA, Shittu MO, Shittu BT. Rifampicin monoresistant mycobacterium tuberculosis among patients visiting chest clinic, State Specialist Hospital, Akure Nigeria. Int J Res Med Sci; 2014;2:1134-7.

Lawson L, Habib AG, Okobi MI. Pilot study on multidrug resistant tuberculosis in Nigeria. Ann Afr Med 2010;9:184-187.

Idigbe O, Sofola T, Akinosho R. Initial drug resistance tuberculosis amongst HIV seropositive and seronegative prison inmates in Lagos, Nigeria. Int Conf AIDS. 1998;12:137.

Otu A, Umoh V, Habib A. Drug resistance among pulmonary tuberculosis patients in Calabar, Nigeria. Pulmonary Med. 2013; 2013:235190.

Adetunji SO, Donbraye E, Ekong MJ. HIV infection among rifampicin resistant tuberculosis patients in Ibadan, Southwest Nigeria. World Journal of Medical Science. 2018;15(4):139-143.

Coovadia YM, Mahomed S, Pillay M. Rifampicin mono-resistance in mycobacterium tuberculosis in kwazulu-Natal, South Africa: A significant phenomenon in high prevalence Tb/HIV Region. PLos One. 2013;8:e77712.

Wiwing V, Widysanto A, Lugito NP. Mycobacterium tuberculosis resistance pattern against firstline drugs in patients from urban areas. Int J Mycobacteriol. 2015;4:302-5.

Gambo Aliyu, Samer S. El-Kamary, Alash’le Abimiku. Mycobacterial etiology of pulmonary tuberculosis and association with HIV infection and multidrug resistance in Northern Nigeria. Hindawi Publishing Corporation Tuberculosis Research and Treatment. 2013;9.
DOI: 10.1155/2013/650561

Sani RA, Garba SA., Oyeleke SB. Prevalence of pulmonary tuberculosis (PTB) in Minna and Suleja Niger State, Nigeria American Journal of Medicine and Medical Sciences. 2015;5(6):287-291.
DOI: 10.5923/j.ajmms.20150506.04

Kehinde AO, Okesola AO. Epidemiology of clinical isolates of Mycobacterium tuberculosis at Ibadan, Nigeria, Nigeria Journal of. Physiology and Sciences. 2010;25135–138.

World Health Organization. Global tuberculosis control: epidemiology, planning, financing: RIF. 2013;1(5):218-223. ISSN: 1837-6746.

Taura DW, Sale IT, Mohammed Y. The prevalence of tuberculosis in patients attending the infectious diseases hospital, Kano, Nigeria. Int. Jor. P. App. Scs. 2008; 2:63-69.

Imam TS, Oyeyi TIA. Retrospective study of pulmonary tuberculosis (PTB) Prevalence amongst patients attending infectious diseases hospital (IDH) in Kano, Nigeria. Bayero Journal of Pure and Applied Sciences. 2008;1:10-15.

Ani AE, Idoko J, Dalyop YB. Drug Resistant profile of mycobacterium tuberculosis isolates from pulmonary tuberculosis patients in Jos, Nigeria. Trans R Soc Trop Med Hyg. 2009;103:67-71.